Skip to content Inauguração emGrand opening inInauguración en --d --h --m --s · Cadastro VIP ›· VIP sign-up ›· Registro VIP › Abrimos hoje · aguardeWe open today · hold onAbrimos hoy · aguarde Loja aberta! Entrar ›Store open! Enter ›¡Tienda abierta! Entrar ›
Eagle Pharma
Track order WhatsApp

KNOWLEDGE · COMPOUNDS

Semaglutide

Also known as: Semaglutida · Ozempic · Wegovy · Rybelsus

MetabolicFDA approved
Ask Eagle AI about this compound

Overview

Written by EagleThis description was written by Eagle in each of the three languages. It is not imported text and carries no translation warning. What it says comes from the compound’s own composition, its pharmacological class and what the library records — no efficacy claim, and no Eagle recommendation of use.

A página separa os esquemas injetável e oral e registra o status aprovado das apresentações de referência.

Semaglutide is catalogued under Metabolic. 12 Eagle articles in this library reference this compound.

Category
Metabolic
Research stage
FDA approved — Aprovado pela FDA Original in PT-BR
Eagle articles on this compound
12 Eagle articles

Mechanism

O site descreve semaglutida como agonista do receptor de GLP-1, com versões injetáveis semanais e comprimido oral diário. Original in PT-BR

Eagle articles on this compound

Chemical information

CAS
Not recorded in the source.
Molecular formula
Not recorded in the source.
Molecular weight
Not recorded in the source.
Sequence
Not recorded in the source.
Amino acids
Not recorded in the source.
Solubility
Not recorded in the source.
Stability
Not recorded in the source.
Half-life
Cerca de 7 dias Original in PT-BR
Bioavailability
Not recorded in the source.
Onset
Not recorded in the source.
Routes
Subcutânea · Oral

Research references

No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.

  • STEP 1 (Wilding et al., NEJM 2021) — estudo citado pelo site; 14,9% de perda de peso média em 68 semanas com 2,4 mg contra 2,4% com placebo. Original in PT-BR

    Year: 2021Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

Safety

No safety information recorded in the source.

Lab tests named in the source

  • Painel metabólico abrangente (CMP)
  • Perfil lipídico
  • Pressão arterial e frequência cardíaca de repouso

The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.

Reported protocols

Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.

Vial sizes: 2 mg · 3 mg · 5 mg · 10 mg — Peptide Calculator

Interactions

These relations were written by Eagle from its own curated library, one by one, and each states what the library records and what it does not. They are not verified clinical evidence: there is no PMID, no population or model and no degree of certainty behind them. «Compatible» and «Caution» describe what the library records about the pair, not an Eagle authorisation or prohibition, and none of this is medical advice.

Caution

  • Tirzepatide

    Overlapping GLP-1 agonism. The library compares the two on tolerability — tirzepatide is described as better tolerated, with less nausea — and never as a combination.

Related

← Back to knowledge area